In Vivo Observation of Endothelial Cell-Assisted Vascularization in Pancreatic Cancer Xenograft Engineering

다국어 초록 (Multilingual Abstract)

In this study, for better understanding of patient-derived xenograft (PDX) generation, angiogenic characteristics during PDX cancerous tissue generation was investigated with different initial cell seeding conditions in the hydrogel. We monitored the angiogenic changes during the formation of in vivo cancer cell line xenografts induced by endothelial cells.
Our in vivo cancer tissue formation system was designed with the assistance of tissue engineering technology to mimic patient-derived xenograft formation. Endothelial cells and MIA PaCa-2 pancreatic carcinoma cells were encapsulated in fibrin gel at different mixing configurations and subcutaneously implanted into nude mice. To investigate the effect of the initial cancerous cell distribution in the fibrin gel, MIA PaCa-2 cells were encapsulated as a homogeneous cell distribution or as a cell aggregate, with endothelial cells homogeneously distributed in the fibrin gel. Histological observation of the explanted tissues after different implantation periods revealed three different stages: isolated vascular tubes, leaky blood vessels, and mature cancerous tissue formation. The in vivo engineered cancerous tissues had leaky blood vessels with low expression of the vascular tight junction marker CD31. Under our experimental conditions, complex cancer-like tissue formation was most successful when tumorous cells and endothelial cells were homogeneously mixed in the fibrin gel. The present study implies that tumorous xenograft tissue formation can be achieved with a low number of initial cells and that effective vascularization conditions can be attained with a limited volume of patient-derived cancer tissue. Endothelial cellassisted vascularization can be a potent choice for the effective development of vascularized cancerous tissues for studying patient-derived xenografts, cancer angiogenesis, cancer metastasis, and anticancer drugs.

참고문헌 (Reference)

1 Folkman J, "Tumor angiogenesis: therapeutic implications" 285 : 1182-1186, 1971

2 Zheng Y, "Tissue engineering: scalable vascularized implants" 15 : 597-599, 2016

3 Langer R, "Tissue engineering" 260 : 920-926, 1993

4 Bianco P, "Stem cells in tissue engineering" 414 : 118-121, 2001

5 Riis P, "Perspectives on the fifth revision of the Declaration of Helsinki" 284 : 3045-3046, 2000

6 Brown KM, "Patientderived xenograft models of colorectal cancer in pre-clinical research: a systematic review" 7 : 66212-66225, 2016

7 Vareslija D, "Patient-derived xenografts of breast cancer" 1501 : 327-336, 2017

8 Izumchenko E, "Patient-derived xenografts as tools in pharmaceutical development" 99 : 612-621, 2016

9 Harris AL, "Patient-derived tumor xenograft models for melanoma drug discovery" 11 : 895-906, 2016

10 Eyre R, "Patient-derived mammosphere and xenograft tumour initiation correlates with progression to metastasis" 21 : 99-109, 2016

11 Steinkamp MP, "Ovarian tumor attachment, invasion, and vascularization reflect unique microenvironments in the peritoneum: insights from xenograft and mathematical models" 3 : 97-, 2013

12 Pina S, "Natural-based nanocomposites for bone tissue engineering and regenerative medicine: a review" 27 : 1143-1169, 2015

13 Young JL, "Nanoscale and mechanical properties of the physiological cell-ECM microenvironment" 343 : 3-6, 2016

14 홍소영, "Multilayered Engineered Tissue Sheets for Vascularized Tissue Regeneration" 한국조직공학과 재생의학회 14 (14): 371-381, 2017

15 Rao RR, "Matrix composition regulates three-dimensional network formation by endothelial cells and mesenchymal stem cells in collagen/fibrin materials" 15 : 253-264, 2012

16 Hoganson DM, "Lung tissue engineering" 19 : 1227-1239, 2014

17 Szabo DJ, "Long-term cultures of human cornea limbal explants form 3D structures ex vivo-implications for tissue engineering and clinical applications" 10 : e0143053-, 2015

18 Kiyuna T, "Labeling the stroma of a patient-derived orthotopic xenograft (PDOX) mouse model of undifferentiated pleomorphic soft-tissue sarcoma with red fluorescent protein for rapid non-invasive imaging for drug screening" 118 : 361-365, 2017

19 Pham K, "Isolation of pancreatic cancer cells from a patient-derived xenograft model allows for practical expansion and preserved heterogeneity in culture" 186 : 1537-1546, 2016

20 Andrade SS, "Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis-influence of platelets and fibrin bundles on the behavior of breast tumor cells" 8 : 16851-16874, 2017

21 Takakura K, "Inhibition of cell proliferation and growth of pancreatic cancer by silencing of carbohydrate sulfotransferase 15 in vitro and in a xenograft model" 10 : e0142981-, 2015

22 Fong EL, "Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening" 11 : 2040-2050, 2014

23 Zhang K, "Heparin/collagen encapsulating nerve growth factor multilayers coated aligned PLLA nanofibrous scaffolds for nerve tissue engineering" 105 : 1900-1910, 2017

24 Kim KM, "Failure of a patient-derived xenograft for brain tumor model prepared by implantation of tissue fragments" 16 : 43-, 2016

25 Lee HW, "Facilitating tailored therapeutic strategies for glioblastoma through an orthotopic patient-derived xenograft platform" 31 : 269-283, 2016

26 Aparicio S, "Examining the utility of patientderived xenograft mouse models" 15 : 311-316, 2015

27 Morton CL, "Establishment of human tumor xenografts in immunodeficient mice" 2 : 247-250, 2007

28 Zamora DO, "Enhanced wound vascularization using a dsASCs seeded FPEG scaffold" 16 : 745-757, 2013

29 Sun JD, "Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer" 16 : 438-449, 2015

30 Minchinton AI, "Drug penetration in solid tumours" 6 : 583-592, 2006

31 Sugimoto K, "Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patientderived xenograft cells" 5 : 13054-, 2015

32 Paez-Ribes M, "Development of patient derived xenograft models of overt spontaneous breast cancer metastasis: a cautionary note" 11 : e0158034-, 2016

33 Chokshi C, "Development of a patient-derived xenograft model using brain tumor stem cell systems to study cancer" 1458 : 231-245, 2016

34 Zhang Q, "Decellularized skin/adipose tissue flap matrix for engineering vascularized composite soft tissue flaps" 35 : 166-184, 2016

35 Kawaguchi T, "Current update of patient-derived xenograft model for translational breast cancer research" 22 : 131-139, 2017

36 Lai Y, "Current status and perspectives of patient-derived xenograft models in cancer research" 10 : 106-, 2017

37 Koolwijk P, "Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity" 132 : 1177-1188, 1996

38 Karam JP, "Combining adult stem cells and polymeric devices for tissue engineering in infarcted myocardium" 33 : 5683-5695, 2012

39 Carpenter AE, "Cell profiler: image analysis software for identifying and quantifying cell phenotypes" 7 : R100-, 2006

40 Zhao H, "Cabozantinib inhibits tumor growth and metastasis of a patientderived xenograft model of papillary renal cell carcinoma with MET mutation" 18 : 863-871, 2017

41 Shivaji Kashte, "Artificial Bone via Bone Tissue Engineering: Current Scenario and Challenges" 한국조직공학과 재생의학회 14 (14): 1-14, 2017

42 Fritsch M, "Application of a patient derived xenograft model for predicative study of uterine fibroid disease" 10 : e0142429-, 2015

43 Nakatsu MN, "Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1" 66 : 102-112, 2003

44 Bishi DK, "A patient-inspired ex vivo liver tissue engineering approach with autologous mesenchymal stem cells and hepatogenic serum" 5 : 1058-1070, 2016

45 Bertotti A, "A molecularly annotated platform of patient-derived xenografts (''xenopatients'') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer" 1 : 508-523, 2011